The number of lung cancer cases in people who have never smoked is increasing. The disease is different from lung cancer ...

Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous ...

Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response (MPR) rates ...

A new "liquid biopsy" test can help fast-track lung cancer patients to receive targeted therapy up to two weeks earlier, ...

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

A mother-of-two from Carlisle says she has been given her life back after receiving targeted cancer treatment.

England's NHS pioneers a revolutionary blood test for faster cancer diagnosis and treatment. This 'liquid biopsy' detects ...

(NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted ...

Suresh S. Ramalingam, MD, FACP, FASCO, emphasizes the role of community oncologists in translating new advancements in lung cancer research into widespread patient benefit.

The authorisation comes three months after the MHRA approved Johnson & Johnson’s Lazcluze (lazertinib), which is also ...

Doctors and researchers are constantly working to find new ways to catch cancers earlier, and help you beat it if it happens.

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer ...